Lipopolysaccharides (LPS) (Escherichia coli 0111:B4, vaccine adjuvant)

Cat.No.

DADF-066

Product Name

Subclassification

Vaccine grade-PRR Ligands-based adjuvant

Classification

Adjuvant

Storage

Shipped at room temperature and it should be stored at 2-8°C. Long term storage at -20°C for upto 2 years. Avoid repeated freeze thaw cycles.

Recommended Usage

The product is soluble in water (5 mg/ml) or cell culture medium (1 mg/ml) yielding a hazy, faint yellow solution. A more oncentrated, though still hazy, solution (20 mg/ml) has been achieved in aqueous saline after vortexing and warming to 70-80 °C. For cell culture use, LPS should be reconstituted by adding 1 ml of sterile balanced salt solution or cell culture medium to a vial (1 mg) and swirling gently until the powder dissolves. Solutions can be further diluted to the desired working concentration with additional sterile balanced salt solutions or cell culture media.

Description

Lipopolysaccharides (LPS) are characteristic components of the cell wall of Gram-negative bacteria. LPS and its lipid A moiety stimulate cells of the innate immune system by the Toll-like receptor 4 (TLR4), a member of the Toll-like receptor protein family, which recognizes common pathogen-associated molecular-patterns (PAMPs). This product is phenol extracted from E. coli serotype O111:B4. This LPS serotype has been used to stimulate B-cells22 and induce NOS in human hepatocytes. Bacteria with common serotypes have surface antigens (group O, group H, or LPS) which generate the same antibody response.
Solubility: water (4.9-5.10 mg/ml), cell culture medium (1 mg/ml)
Turbidity: Slightly hazy
Prot. Content (%): 0.41
Potency: 600000 EU/mg

Format

lyophilized powder; sterile